Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

BACKGROUND The atherosclerotic progression-reducing effect of LDL cholesterol (LDL-C) lowering has been established in subjects with severe atherosclerotic disease but not in persons with elevated LDL cholesterols without severe atherosclerosis. KAPS (Kuopio Atherosclerosis Prevention Study) is the first population-based trial in the primary prevention of carotid and femoral atherosclerosis. METHODS AND RESULTS The eligibility requirements were serum LDL-C > or = 4.0 mmol/L and total cholesterol < 7.5 mmol/L. Out of a geographically defined population, 447 men aged 44 to 65 years (mean, 57) were randomized to pravastatin (40 mg/d) or placebo for 3 years. Less than 10% of the subjects had prior myocardial infarction. Thirty-nine men discontinued study medication; however, efficacy data were available for 424 men. The primary outcome was the rate of carotid atherosclerotic progression, measured as the linear slope over annual ultrasound examinations in the average of the maximum carotid intima-media thickness (IMT) of the far wall of up to four arterial segments (the right and left distal common carotid artery and the right and left carotid bulb). For the carotid arteries, at the overall mean baseline IMT of 1.66 mm, the rate of progression of carotid atherosclerosis was 45% (95% CI, 16 to 69%) less in the pravastatin (0.017 mm/y) than the placebo (0.031 mm/y) group (P = .005). In the common carotid artery there was a treatment effect of 66% (95% CI, 30 to 95%; pravastatin 0.010 mm/y; placebo 0.029 mm/y; P < .002) at the overall mean baseline IMT of 1.35 mm. A treatment effect of 30% (95% CI, -1% to 54%) was found for the carotid bulb (pravastatin, 0.028; placebo, 0.040; P = .056) at the overall mean baseline IMT of 2.0 mm. The treatment effect was larger in subjects with higher baseline IMT values, in smokers and in those with low plasma vitamin E levels. There was no significant treatment effect on atherosclerotic progression in the femoral arteries. CONCLUSIONS These data establish the antiatherogenic effect of LDL-C lowering by pravastatin in hypercholesterolemic men in a primary prevention setting and suggest a greater effect in smokers than in nonsmokers.

[1]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[2]  J. Salonen,et al.  Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  J. Toole,et al.  Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. , 1986, Stroke.

[4]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[5]  R. Salonen,et al.  Precision and reproducibility of ultrasonographic measurement of progression of common carotid artery atherosclerosis , 1993, The Lancet.

[6]  J. Salonen,et al.  Determinants of carotid intima‐media thickness: a population‐based ultrasonography study in Eastern Finnish men , 1991, Journal of internal medicine.

[7]  J. Salonen,et al.  Smoking, blood pressure and serum cholesterol as risk factors of acute myocardial infarction and death among men in Eastern Finland. , 1981, European heart journal.

[8]  Salonen Jt.  Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. , 1988 .

[9]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[10]  R Rauramaa,et al.  Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. , 1988, Arteriosclerosis.

[11]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[12]  J. Salonen,et al.  Measurement of intima-media thickness of common carotid arteries with high-resolution B-mode ultrasonography: inter- and intra-observer variability. , 1991, Ultrasound in medicine & biology.

[13]  C. Furberg,et al.  Pravastatin, lipids, and major coronary events. , 1994, The American journal of cardiology.

[14]  D. J. Finney.  Statistical Method in Biological Assay , 1966 .

[15]  J. Salonen,et al.  Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial. , 1994, European journal of clinical nutrition.

[16]  J. Salonen,et al.  Ultrasound B-mode imaging in observational studies of atherosclerotic progression. , 1993, Circulation.

[17]  R. Schifman,et al.  Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement. , 1978, Clinical chemistry.

[18]  J. Salonen,et al.  Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. , 1990, Atherosclerosis.

[19]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[20]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[21]  J. Wikstrand,et al.  Methodological considerations of ultrasound investigation of intima‐media thickness and lumen diameter , 1994, Journal of internal medicine.

[22]  K. Gould,et al.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.

[23]  S. Kelsey,et al.  The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[24]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[25]  L. Solberg,et al.  Risk factors and atherosclerotic lesions. A review of autopsy studies. , 1983, Arteriosclerosis.

[26]  H. Hodis,et al.  Arterial imaging and atherosclerosis reversal , 1994 .

[27]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[28]  H. Hodis,et al.  George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  J. Salonen,et al.  Risk factors for carotid and femoral atherosclerosis in hypercholesterolaemic men , 1994, Journal of internal medicine.

[30]  J. Toole,et al.  Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. , 1990, Circulation.

[31]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.